Walvax Biotechnology Co., Ltd. (SHE:300142)

China flag China · Delayed Price · Currency is CNY
11.45
+0.22 (1.96%)
Jun 9, 2026, 3:10 PM CST
Market Cap18.31B +10.7%
Revenue (ttm)2.40B -10.6%
Net Income285.77M +118.7%
EPS0.18 +115.5%
Shares Out 1.60B
PE Ratio64.53
Forward PE61.07
Dividend0.16 (1.38%)
Ex-Dividend DateJan 9, 2026
Volume46,033,127
Open11.99
Previous Close11.23
Day's Range10.98 - 11.99
52-Week Range10.05 - 16.23
Beta0.39
Analystsn/a
Price Targetn/a
Earnings DateAug 24, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis c... [Read more]

Sector Healthcare
Founded 2001
Employees 1,981
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300142
Full Company Profile

Financial Performance

In 2025, Walvax Biotechnology's revenue was 2.42 billion, a decrease of -14.29% compared to the previous year's 2.82 billion. Earnings were 177.74 million, an increase of 25.03%.

Financial Statements